KR20240168984A - 항-c5 항체 크로발리맙을 이용하는 길랭 바레 증후군의 치료 또는 예방을 위한 용량 및 투여 요법 - Google Patents

항-c5 항체 크로발리맙을 이용하는 길랭 바레 증후군의 치료 또는 예방을 위한 용량 및 투여 요법 Download PDF

Info

Publication number
KR20240168984A
KR20240168984A KR1020247032946A KR20247032946A KR20240168984A KR 20240168984 A KR20240168984 A KR 20240168984A KR 1020247032946 A KR1020247032946 A KR 1020247032946A KR 20247032946 A KR20247032946 A KR 20247032946A KR 20240168984 A KR20240168984 A KR 20240168984A
Authority
KR
South Korea
Prior art keywords
antibody
subject
ivig
dose
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032946A
Other languages
English (en)
Korean (ko)
Inventor
사이몬 베르트랑 마리 부아투아
게이스케 고탄다
겐지 시노미야
알렉상드르 앙투안 베르나르 소스텔리
앙투안 폴 막상스 수브레
Original Assignee
에프. 호프만-라 로슈 아게
추가이 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게, 추가이 세이야쿠 가부시키가이샤 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20240168984A publication Critical patent/KR20240168984A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020247032946A 2022-04-04 2023-04-03 항-c5 항체 크로발리맙을 이용하는 길랭 바레 증후군의 치료 또는 예방을 위한 용량 및 투여 요법 Pending KR20240168984A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22166585.4 2022-04-04
EP22166585 2022-04-04
PCT/EP2023/058608 WO2023194273A1 (en) 2022-04-04 2023-04-03 Dosage and administration regimen for the treatment or prevention of guillan-barré syndrome by the use of the anti-c5 antibody crovalimab

Publications (1)

Publication Number Publication Date
KR20240168984A true KR20240168984A (ko) 2024-12-02

Family

ID=81327202

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032946A Pending KR20240168984A (ko) 2022-04-04 2023-04-03 항-c5 항체 크로발리맙을 이용하는 길랭 바레 증후군의 치료 또는 예방을 위한 용량 및 투여 요법

Country Status (11)

Country Link
US (1) US20250236662A1 (https=)
EP (1) EP4504774A1 (https=)
JP (1) JP2025511382A (https=)
KR (1) KR20240168984A (https=)
CN (1) CN118974082A (https=)
AU (1) AU2023249891A1 (https=)
CA (1) CA3251880A1 (https=)
IL (1) IL314751A (https=)
MX (1) MX2024012073A (https=)
TW (1) TW202404632A (https=)
WO (1) WO2023194273A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9388235B2 (en) * 2006-09-05 2016-07-12 Alexion Pharmaceuticals, Inc. Methods and compositions for the treatment of antibody mediated neuropathies
BR112017011235A2 (pt) 2014-12-19 2018-02-06 Chugai Pharmaceutical Co Ltd anticorpos anti-c5 e métodos de uso
DK3658184T5 (da) * 2017-07-27 2024-08-26 Alexion Pharma Inc Højkoncentrerede anti-c5-antistofformuleringer
CR20220040A (es) * 2019-07-31 2022-03-02 Hoffmann La Roche Régimen de dosificación y administración para el tratamiento o prevención de enfermedades relacionadas con c5 mediante el uso del anticuerpo anti-c5 crovalimab

Also Published As

Publication number Publication date
MX2024012073A (es) 2024-11-08
CN118974082A (zh) 2024-11-15
WO2023194273A1 (en) 2023-10-12
US20250236662A1 (en) 2025-07-24
EP4504774A1 (en) 2025-02-12
CA3251880A1 (en) 2023-10-12
AU2023249891A1 (en) 2024-08-08
AU2023249891A9 (en) 2024-08-15
JP2025511382A (ja) 2025-04-15
TW202404632A (zh) 2024-02-01
IL314751A (en) 2024-10-01

Similar Documents

Publication Publication Date Title
JP7663559B2 (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
AU2008265974B2 (en) Use of TACI-Ig fusion protein such as atacicept for the manufacture of a medicament for treating Lupus Erythematosus
WO2019186369A1 (en) Methods of treating chronic spontaneous urticaria using ligelizumab
US20220127345A1 (en) Methods of Reducing Tau in Human Subjects
KR20240168984A (ko) 항-c5 항체 크로발리맙을 이용하는 길랭 바레 증후군의 치료 또는 예방을 위한 용량 및 투여 요법
US20220112294A1 (en) Methods Of Treating Type 2 Diabetes Mellitus Using Glucagon Receptor Antagonistic Antibodies
KR20240168923A (ko) 항-c5 항체 크로발리맙을 사용하여 길랭-바레 증후군을 치료 또는 예방하기 위한 투여량 및 투여 요법
CN104395343A (zh) 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案
US20240239911A1 (en) Treatment for lupus nephritis using anti-baffr antibodies
Valdes et al. Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: a retrospective review
JP7739537B2 (ja) Ｆｖｉｉｉ模倣二重特異性抗体を２ヶ月に１回投与する方法
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
RU2783540C2 (ru) Способы лечения хронической спонтанной крапивницы с применением лигелизумаба
WO2025096435A1 (en) Treatment of complement-associated renal diseases
EA050381B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов
CN118786147A (zh) 每月一次施用fviii模拟双特异性抗体的方法
EA052839B1 (ru) Способы снижения уровня тау-белка у человеческих индивидов

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000